AUC

New Head Basketball Coach Returns Home to Clark Atlanta University

Retrieved on: 
Friday, September 23, 2022

ATLANTA, Sept. 23, 2022 /PRNewswire/ -- In a loop that took him from Clark Atlanta University (CAU) to the University of Arkansas at Little Rock, then to neighboring Morehouse College, Alfred Jordan is returning home to where it all began for him: he is the new head basketball coach for the CAU Basketball team.

Key Points: 
  • ATLANTA, Sept. 23, 2022 /PRNewswire/ -- In a loop that took him from Clark Atlanta University (CAU) to the University of Arkansas at Little Rock, then to neighboring Morehouse College, Alfred Jordan is returning home to where it all began for him: he is the new head basketball coach for the CAU Basketball team.
  • But now I'm ready to get to work here at my alma mater Clark Atlanta University."
  • Jordan shared that his foundation as a Clark Atlanta graduate has significantly impacted how he coaches and approaches life.
  • He followed former CAU head coach Darrell Walter to serve for two years as an assistant coach at the University of Arkansas at Little Rock.

Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

Retrieved on: 
Thursday, September 22, 2022

The presentation highlighted BMF-219s ability to improve pancreatic beta cell area and function in two preclinical rat models of diabetes.

Key Points: 
  • The presentation highlighted BMF-219s ability to improve pancreatic beta cell area and function in two preclinical rat models of diabetes.
  • This data provides further support for the potential of BMF-219 as a long-acting, disease modifying treatment for type 2 diabetes.
  • Today we reported direct evidence of BMF-219s ability to increase beta cell area, another key feature of the novel mechanism.
  • BMF-219 also displayed the ability to restore and preserve beta cell function in various type 2 diabetes models.

EQS-News: Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Retrieved on: 
Tuesday, September 20, 2022

Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.

Key Points: 
  • Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.
  • These favorable results allowed a smooth transition to the MAD part of the trial.
  • Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.
  • The unblinded data from the single and multiple ascending dose parts of our phase 1 clinical trial of IMU856 in healthy human subjects revealed a favorable safety, tolerability and pharmacokinetic profile.

African Women Impact Fund launches with USD$60 million commitment to drive an inclusive investment environment

Retrieved on: 
Monday, September 19, 2022

This holds true within the investment space where these prejudices obstruct female entrepreneurship, appointment of women in leadership roles, and empowerment of female fund managers.

Key Points: 
  • This holds true within the investment space where these prejudices obstruct female entrepreneurship, appointment of women in leadership roles, and empowerment of female fund managers.
  • The Initiative has a two-fold agenda of making a commercial impact for investors while empowering women financial leaders to drive growth in Africa.
  • With 20 years' experience in supporting diverse and start-up investment managers on the African continent, we are excited to manage the investments of the African Women Impact Fund and continue the journey of empowerment."
  • These funds will provide capital to existing women owners and women fund managers across different asset classes and African regions.

ACTIF 2022 opens new trade and investment path between the Caribbean and Africa 

Retrieved on: 
Friday, September 16, 2022

The forum opened a new chapter for the relations between the Caribbean and Africa.

Key Points: 
  • The forum opened a new chapter for the relations between the Caribbean and Africa.
  • Held under the theme, 'One People, One Destiny, Uniting and Reimagining Our Future', the forum set in motion various initiatives to further deepen and build new trade and investment relationships between Africa and the Caribbean.
  • The Prime Minister of Barbados - Mia Amor Mottley, expressed pleasure at being selected as the host country for ACTIF 2022.
  • Promotion of trade and investment between Africa and the Caribbean as the forum served as the platform for market identification, building business partnerships, exchange of trade and market information, and co-investments.

Independent Research Finds Underlying Method for C2N’s p-Tau217 Ratio Blood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses

Retrieved on: 
Wednesday, September 14, 2022

Currently available as a unique research tool in Alzheimers clinical studies, C2Ns p-tau217 ratio test is nearing completion of development as a clinical lab test that will help healthcare providers better diagnose Alzheimers disease, particularly when combined with amyloid beta (A) measures from C2Ns existing PrecivityAD clinical blood test .

Key Points: 
  • Currently available as a unique research tool in Alzheimers clinical studies, C2Ns p-tau217 ratio test is nearing completion of development as a clinical lab test that will help healthcare providers better diagnose Alzheimers disease, particularly when combined with amyloid beta (A) measures from C2Ns existing PrecivityAD clinical blood test .
  • The head-to-head comparison measured the diagnostic performance of 10 different tests that quantify plasma phosphorylated-tau concentrations, including the methods underlying C2Ns p-tau217 ratio blood test, to detect abnormal brain amyloid- status and predict future progression to Alzheimer's dementia.
  • The different tests compared in the round-robin study ranged from using mass spectrometry (MS)-based methods to immunoassays to detect one of three phosphorylated tau markers, including p-tau181, p-tau217, and p-tau231.
  • At this years AAIC annual meeting, the company reported its first clinical research experience combining its p-tau217 ratio blood test with its A 42/40 ratio blood test to identify amyloid pathology in individuals with cognitive impairment or dementia.

UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

Retrieved on: 
Tuesday, September 13, 2022

The studys predictive model displayed high diagnostic potential by generating a 0.96 AUC, sensitivity of 92% at 85% specificity, and 92% precision when analyzing CRC samples.

Key Points: 
  • The studys predictive model displayed high diagnostic potential by generating a 0.96 AUC, sensitivity of 92% at 85% specificity, and 92% precision when analyzing CRC samples.
  • Additionally, Stage I/II CRC samples were readily distinguishable from Stage III/IV and resected Stage III/IV CRC samples.
  • Dr. Shema and Mr. Jones were the lead and second author on that publication and have continued to collaboratively develop the underlying technology.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology

Retrieved on: 
Monday, September 12, 2022

Additionally, Stage I/II CRC samples were readily distinguishable from Stage III/IV and resected Stage III/IV CRC samples.

Key Points: 
  • Additionally, Stage I/II CRC samples were readily distinguishable from Stage III/IV and resected Stage III/IV CRC samples.
  • Dr. Shema and Mr. Jones were the lead and second author on that publication and have continued to collaboratively develop the underlying technology.
  • SeqLL Inc. (SeqLL) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Saturday, September 10, 2022

As the first ULK1/2 inhibitor to enter clinical development, these positive initial results represent a significant milestone as we prepare to initiate combination dose escalation later this year.

Key Points: 
  • As the first ULK1/2 inhibitor to enter clinical development, these positive initial results represent a significant milestone as we prepare to initiate combination dose escalation later this year.
  • The preliminary data show DCC-3116 to be a very well-tolerated agent that has demonstrated strong target inhibition of ULK 1/2 from even the lowest tested dose.
  • I look forward to the selection of the combination starting dose and advancing the program into the first combination studies with MEK and KRASG12C inhibitors.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

DGAP-News: Novigenix Announces Discovery of Liquid Biopsy Immunotherapy Response Biomarkers in Metastatic Melanoma

Retrieved on: 
Friday, September 9, 2022

LAUSANNE, SWITZERLAND / ACCESSWIRE / September 9, 2022 / Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of response to immunotherapy and patient monitoring in metastatic melanoma (MM).

Key Points: 
  • LAUSANNE, SWITZERLAND / ACCESSWIRE / September 9, 2022 / Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of response to immunotherapy and patient monitoring in metastatic melanoma (MM).
  • Immune checkpoint inhibitors (ICIs) have become one of the main treatments for patients with metastatic cancer.
  • There is therefore a significant unmet medical need for accurate liquid biopsy precision solutions that can select and monitor patients during ICI therapy.
  • Novigenix is a precision medicine biotech providing a new understanding of the human host response to cancer and its response to therapy.